It can be concluded that the therapeutic mechanism of SPRC is through CBS/H2S‐CD24‐Iκ‐Bα‐NF‐κB pathway to relieve inflammation of ischemic stroke. This evidence concerns the gene NFKB1 and ischemic stroke.